Britta Stordal

Britta Stordal

UNVERIFIED PROFILE

Are you Britta Stordal?   Register this Author

Register author
Britta Stordal

Britta Stordal

Publications by authors named "Britta Stordal"

Are you Britta Stordal?   Register this Author

23Publications

132Reads

-Profile Views

Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.

Exp Cell Res 2015 Aug 12;336(1):1-14. Epub 2014 Dec 12.

Department of Histopathology, Trinity College Dublin, Central Pathology Laboratory, St James's Hospital, Dublin 8, Ireland; Department of Natural Sciences, Hendon Campus, Middlesex University, London NW4 4BT, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00144827140052
Publisher Site
http://dx.doi.org/10.1016/j.yexcr.2014.12.001DOI Listing
August 2015

Non-invasive and non-destructive measurements of confluence in cultured adherent cell lines.

MethodsX 2015 25;2:8-13. Epub 2014 Nov 25.

Department of Histopathology, Trinity College Dublin, Central Pathology Laboratory, St. James's Hospital, Dublin 8, Ireland ; Department of Natural Sciences, Hendon Campus, Middlesex University, London NW4 4BT, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mex.2014.11.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487325PMC
July 2015

Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.

BMC Cancer 2015 Jul 25;15:547. Epub 2015 Jul 25.

Department of Histopathology TCD, Sir Patrick Dun's Laboratory, Central Pathology Laboratory, St James's Hospital, Dublin 8, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1539-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513971PMC
July 2015

OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.

Mol Cancer 2014 Oct 24;13:241. Epub 2014 Oct 24.

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-13-241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219121PMC
October 2014

PARP Inhibitors as P-glyoprotein Substrates.

J Pharm Sci 2014 Jun 3;103(6):1913-20. Epub 2014 Apr 3.

Department of Histopathology, St James' Hospital and Trinity College, Dublin, Dublin 8, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jps.23952DOI Listing
June 2014

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.

Front Oncol 2014 6;4:40. Epub 2014 Mar 6.

National Institute for Cellular Biotechnology, Dublin City University , Dublin , Ireland ; Department of Histopathology, St James' Hospital, Trinity College Dublin , Dublin , Ireland.

View Article

Download full-text PDF

Source
http://journal.frontiersin.org/article/10.3389/fonc.2014.000
Publisher Site
http://dx.doi.org/10.3389/fonc.2014.00040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944788PMC
March 2014

Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells.

Anticancer Res 2014 Jan;34(1):503-7

Department of Histopathology, Trinity College Dublin, 1.18 Sir Patrick Dun Research Laboratory, Central Pathology Building, St James' Hospital, Dublin 8, Ireland.

View Article

Download full-text PDF

Source
January 2014

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Drug Resist Updat 2011 Jun 24;14(3):177-90. Epub 2011 Mar 24.

National Institute for Cellular Biotechnology, Dublin City University, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drup.2011.02.004DOI Listing
June 2011

Citations, citations everywhere but did anyone read the paper?

Authors:
Britta Stordal

Colloids Surf B Biointerfaces 2009 Sep 10;72(2):312; author reply 313. Epub 2009 Apr 10.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.colsurfb.2009.04.001DOI Listing
September 2009

A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1.

Curr Cancer Drug Targets 2009 May;9(3):354-65

National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

View Article

Download full-text PDF

Source
May 2009

ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.

Cancer Chemother Pharmacol 2009 Mar 25;63(4):661-72. Epub 2008 Jun 25.

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital and The University of Sydney, St Leonards, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-008-0783-xDOI Listing
March 2009

Platinum resistance needs the mythbusters.

Toxicol Lett 2008 Aug 10;180(3):230. Epub 2008 Jul 10.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.toxlet.2008.07.003DOI Listing
August 2008

A 39 kDa fragment of endogenous ASK1 suggests specific cleavage not degradation by the proteasome.

IUBMB Life 2008 Mar;60(3):180-4

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital and University of Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/iub.24DOI Listing
March 2008

A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship.

Cancer Treat Rev 2007 Dec 18;33(8):688-703. Epub 2007 Sep 18.

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital and The University of Sydney, St. Leonards, NSW 2065, Australia.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S030573720700098
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2007.07.013DOI Listing
December 2007

Understanding cisplatin resistance using cellular models.

IUBMB Life 2007 Nov;59(11):696-9

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital and University of Sydney, St Leonards, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15216540701636287DOI Listing
November 2007

Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.

Cancer Treat Rev 2007 Jun 23;33(4):347-57. Epub 2007 Mar 23.

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital and University of Sydney, St. Leonards, NSW 2065, Australia.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S030573720700032
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2007.01.009DOI Listing
June 2007

Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance.

Genes Chromosomes Cancer 2006 Dec;45(12):1094-105

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/gcc.20373
Publisher Site
http://dx.doi.org/10.1002/gcc.20373DOI Listing
December 2006

Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.

Cancer Chemother Pharmacol 2006 Aug 10;58(2):256-65. Epub 2005 Nov 10.

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital, 2065 St Leonards, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-005-0148-7DOI Listing
August 2006